Insulet Co. (NASDAQ:PODD) Shares Sold by Tredje AP fonden

Tredje AP fonden lessened its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 50.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,442 shares of the medical instruments supplier's stock after selling 5,441 shares during the period. Tredje AP fonden's holdings in Insulet were worth $1,421,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Integrated Wealth Concepts LLC raised its stake in shares of Insulet by 1.7% during the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier's stock valued at $596,000 after acquiring an additional 42 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Insulet by 1.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock valued at $1,146,000 after acquiring an additional 43 shares in the last quarter. Glenmede Trust Co. NA raised its stake in shares of Insulet by 2.3% during the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier's stock valued at $484,000 after acquiring an additional 47 shares in the last quarter. Graypoint LLC raised its stake in Insulet by 5.3% in the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier's stock worth $243,000 after buying an additional 47 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB raised its stake in Insulet by 9.6% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier's stock worth $140,000 after buying an additional 47 shares in the last quarter.

Remove Ads

Wall Street Analyst Weigh In

A number of brokerages recently commented on PODD. Citigroup boosted their price objective on shares of Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Wells Fargo & Company boosted their price objective on shares of Insulet from $305.00 to $322.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Raymond James reissued an "outperform" rating and issued a $328.00 price objective (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Piper Sandler boosted their price objective on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group boosted their price objective on shares of Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $292.06.

Insider Activity at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.47% of the stock is currently owned by insiders.

Insulet Stock Performance

Shares of PODD traded up $5.35 during trading hours on Wednesday, reaching $265.82. 588,392 shares of the company traded hands, compared to its average volume of 689,494. The stock has a market capitalization of $18.67 billion, a P/E ratio of 45.91, a P/E/G ratio of 3.62 and a beta of 1.29. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46. The business has a fifty day moving average price of $272.30 and a 200-day moving average price of $256.12.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Equities analysts anticipate that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.